Table 1.
Demographic and Cancer Treatment-Related Characteristics (N = 220)
| Variable | Intervention (N = 108) |
Control (N = 112) |
p value |
|---|---|---|---|
| Age at Baseline | p = 0.33 | ||
| Median (Range) | 54 (26–86) | 56 (22–87) | |
| Time on Study (Days) | p = 0.64 | ||
| Median (Range) | 122 (49–482) | 113 (49–378) | |
| Gender | p = 0.89 | ||
| Male | 51 (47%) | 51 (46%) | |
| Female | 57 (53%) | 61 (54%) | |
| Ethnicity/Race | p = 0.95 | ||
| Caucasian | 94 (87%) | 98 (87%) | |
| Minority | 4 (4%) | 3 (3%) | |
| Missing | 10 (9%) | 11 (10%) | |
| Working Status | p = 0.49 | ||
| Working | 72 (67%) | 79 (71%) | |
| Not working | 29 (27%) | 23 (20%) | |
| Missing | 7 (6%) | 10 (9%) | |
| Clinical Service | p = 0.83 | ||
| Medical Oncology | 95 (88%) | 100 (89%) | |
| Radiation Oncology | 13 (12%) | 12 (11%) | |
| Cancer Diagnosisa | p = 0.83 | ||
| Breast | 34 (31%) | 42 (38%) | |
| Head and Neck | 17 (16%) | 14 (12%) | |
| Colorectal | 16 (15%) | 14 (12%) | |
| Prostate | 12 (11%) | 10 (9%) | |
| Esophageal | 7 (6%) | 3 (3%) | |
| Testicular | 7 (6%) | 5 (4%) | |
| Gastrointestinal Other | 4 (4%) | 2 (2%) | |
| Other | 4 (4%) | 3 (3%) | |
| Sarcoma | 3 (3%) | 0 | |
| Bladder | 2 (2%) | 9 (8%) | |
| Gastric | 2 (2%) | 5 (4%) | |
| Pancreatic | 0 | 1 (1%) | |
| Unknown Primary | 0 | 4 (4%) | |
| Stage | p = 0.29 | ||
| I | 14 (13%) | 19 (16%) | |
| II | 30 (28%) | 29 (26%) | |
| III | 30 (28%) | 22 (20%) | |
| IV | 30 (28%) | 40 (36%) | |
| Missing | 4 (4%) | 2 (2%) | |
| Chemotherapy Type | p = 0.98 | ||
| Taxane Only | 62 (58%) | 62 (55%) | |
| Platinum Only | 39 (36%) | 42 (38%) | |
| Platinum and Taxane | 7 (6%) | 8 (7%) | |
| Cumulative Dose Categoryb | p = 0.31 | ||
| Low Dosec | 25 (23%) | 26 (23%) | |
| Moderate Dosed | 35 (32%) | 48 (43%) | |
| High Dosee | 47 (44%) | 37 (33%) | |
| Missing | 1 (1%) | 1 (%) | |
| Neurotoxic Chemotherapy Dose Reduction | p = 0.60 | ||
| None | 96 (89%) | 104 (93%) | |
| Neuropathy-Related | 9 (8%) | 6 (5%) | |
| Other Symptom-Relatedf | 3 (3%) | 2 (2%) |
This table describes the demographic characteristics of the patients at baseline
aTo compare distribution of cancer diagnosis for intervention versus control, the diagnoses with < 10 observations are grouped together into another category (i.e., esophageal, testicular, gastrointestinal, miscellaneous, sarcoma, bladder, gastric, pancreatic and unknown primary)
bFor participants receiving multiple neurotoxic chemotherapy agents, dose category was determined based on the highest dose of one of the specific agents they were receiving
cPaclitaxel < 700 mg/m2; Oxaliplatin < 800 mg/m2; Docetaxel < 300 mg/m2; Cisplatin < 300 mg/m2
dPaclitaxel 700–1400 mg/m2; Oxaliplatin 800–1000 mg/m2; Docetaxel 300–600 mg/m2; Cisplatin 300–600 mg/m2
ePaclitaxel > 1400 mg/m2; Oxaliplatin > 1000 mg/m2; Docetaxel > 600 mg/m2; Cisplatin > 600 mg/m2
fNeurotoxic chemotherapy dose reduction due to other symptom-related causes included fatigue, pain, skin changes, bowel problems, or breathing problems